+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      A Radioimmunoassay for Pregnancy Associated Protein, β 1 SP 1: Levels in Pregnancy, Trophoblastic and Neoplastic Disease

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          A radioimmunoassay system for the glycoprotein β<sub>1</sub>SP<sub>1</sub>,, one of the pregnancy-associated proteins, has been set up. β<sub>1</sub>SP<sub>1</sub> levels in normal pregnancy have been established transversally. Clearance (t½) from the circulation postpartum ranged from 1.4 to 1.8 days. Several patients with trophoblastic disease, e.g., mola hydatidosa, choriocarcinoma and embryonic cell carcinoma, were followed longitudinally. Human chorionic gonadotropin (hCG), a highly reliable tumor marker in trophoblastic disease, has been determined concomitantly by radioimmunoassay. In all instances, hCG proved to be a better indicator of the presence of a tumor, because by the time β<sub>1</sub>SP<sub>1</sub>became undetectable, hCG could still be detected. Samples from a large multicenter study on trophoblastic disease were studied: out of 100 positive for hCG, β<sub>1</sub>SP<sub>1</sub> could be detected in 86; however, out of 21 samples in which hCG was not detectable, 1 was found to be positive for β<sub>1</sub>SP<sub>1</sub> . In a number of samples from patients with bronchial carcinoma, no β<sub>1</sub>SP<sub>1</sub>could be detected.

          Related collections

          Author and article information

          Hormone Research in Paediatrics
          S. Karger AG
          25 November 2008
          : 12
          : 5
          : 245-252
          Department of Obstetrics and Gynaecology, St. Radboud Ziekenhuis, University of Nijmegen, Nijmegen
          179127 Horm Res 1980;12:245–252
          © 1980 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8
          Original Paper


          Comment on this article